Literature DB >> 26240275

Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia.

Pavlina Janovska1, Lucie Poppova2, Karla Plevova2, Hana Plesingerova2, Martin Behal1, Marketa Kaucka1, Petra Ovesna3, Michaela Hlozkova4, Marek Borsky5, Olga Stehlikova5, Yvona Brychtova5, Michael Doubek2, Michaela Machalova6, Sivasubramanian Baskar7, Alois Kozubik8, Sarka Pospisilova2, Sarka Pavlova2, Vitezslav Bryja9.   

Abstract

PURPOSE: ROR1, a receptor in the noncanonical Wnt/planar cell polarity (PCP) pathway, is upregulated in malignant B cells of chronic lymphocytic leukemia (CLL) patients. It has been shown that the Wnt/PCP pathway drives pathogenesis of CLL, but which factors activate the ROR1 and PCP pathway in CLL cells remains unclear. EXPERIMENTAL
DESIGN: B lymphocytes from the peripheral blood of CLL patients were negatively separated using RosetteSep (StemCell) and gradient density centrifugation. Relative expression of WNT5A, WNT5B, and ROR1 was assessed by quantitative real-time PCR. Protein levels, protein interaction, and downstream signaling were analyzed by immunoprecipitation and Western blotting. Migration capacity of primary CLL cells was analyzed by the Transwell migration assay.
RESULTS: By analyzing the expression in 137 previously untreated CLL patients, we demonstrate that WNT5A and WNT5B genes show dramatically (five orders of magnitude) varying expression in CLL cells. High WNT5A and WNT5B expression strongly associates with unmutated IGHV and shortened time to first treatment. In addition, WNT5A levels associate, independent of IGHV status, with the clinically worst CLL subgroups characterized by dysfunctional p53 and mutated SF3B1. We provide functional evidence that WNT5A-positive primary CLL cells have increased motility and attenuated chemotaxis toward CXCL12 and CCL19 that can be overcome by inhibitors of Wnt/PCP signaling.
CONCLUSIONS: These observations identify Wnt-5a as the crucial regulator of ROR1 activity in CLL and suggest that the autocrine Wnt-5a signaling pathway allows CLL cells to overcome natural microenvironmental regulation. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26240275      PMCID: PMC4716000          DOI: 10.1158/1078-0432.CCR-15-0154

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  35 in total

1.  ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL).

Authors:  Sarah J Richardson; Christine Matthews; Mark A Catherwood; H Denis Alexander; B Sean Carey; Joanna Farrugia; Anne Gardiner; Sarah Mould; David Oscier; J Adrian Copplestone; Archibald G Prentice
Journal:  Blood       Date:  2005-12-06       Impact factor: 22.113

2.  Wnt-5a induces Dishevelled phosphorylation and dopaminergic differentiation via a CK1-dependent mechanism.

Authors:  Vítezslav Bryja; Gunnar Schulte; Nina Rawal; Alexandra Grahn; Ernest Arenas
Journal:  J Cell Sci       Date:  2007-01-23       Impact factor: 5.285

3.  Wnt-3a utilizes a novel low dose and rapid pathway that does not require casein kinase 1-mediated phosphorylation of Dvl to activate beta-catenin.

Authors:  Vítezslav Bryja; Gunnar Schulte; Ernest Arenas
Journal:  Cell Signal       Date:  2006-08-30       Impact factor: 4.315

4.  Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia - long-term follow up of patients with different percentages of mutations.

Authors:  Terry J Hamblin; Zadie A Davis; David G Oscier
Journal:  Br J Haematol       Date:  2007-12-05       Impact factor: 6.998

5.  Beta-arrestin is a necessary component of Wnt/beta-catenin signaling in vitro and in vivo.

Authors:  Vítezslav Bryja; Dietmar Gradl; Alexandra Schambony; Ernest Arenas; Gunnar Schulte
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-10       Impact factor: 11.205

Review 6.  Multiplicity of the interactions of Wnt proteins and their receptors.

Authors:  Akira Kikuchi; Hideki Yamamoto; Shosei Kishida
Journal:  Cell Signal       Date:  2006-11-16       Impact factor: 4.315

7.  Genomic aberrations and survival in chronic lymphocytic leukemia.

Authors:  H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

8.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Authors:  R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

9.  Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.

Authors:  Sivasubramanian Baskar; Ka Yin Kwong; Thomas Hofer; Jessica M Levy; Michael G Kennedy; Elinor Lee; Louis M Staudt; Wyndham H Wilson; Adrian Wiestner; Christoph Rader
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

10.  Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

Authors:  P Baliakas; A Hadzidimitriou; L-A Sutton; D Rossi; E Minga; N Villamor; M Larrayoz; J Kminkova; A Agathangelidis; Z Davis; E Tausch; E Stalika; B Kantorova; L Mansouri; L Scarfò; D Cortese; V Navrkalova; M J J Rose-Zerilli; K E Smedby; G Juliusson; A Anagnostopoulos; A M Makris; A Navarro; J Delgado; D Oscier; C Belessi; S Stilgenbauer; P Ghia; S Pospisilova; G Gaidano; E Campo; J C Strefford; K Stamatopoulos; R Rosenquist
Journal:  Leukemia       Date:  2014-06-19       Impact factor: 11.528

View more
  23 in total

1.  Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.

Authors:  Hanna Karvonen; David Chiron; Wilhelmiina Niininen; Sara Ek; Mats Jerkeman; Elaheh Moradi; Matti Nykter; Caroline A Heckman; Olli Kallioniemi; Astrid Murumägi; Daniela Ungureanu
Journal:  Blood Adv       Date:  2017-11-09

2.  STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Alessandra Ferrajoli; Jan A Burger; Prithviraj Bose; Phillip A Thompson; Nitin Jain; William G Wierda; Orit Uziel; Michael J Keating; Zeev Estrov
Journal:  J Immunol       Date:  2019-10-23       Impact factor: 5.422

3.  High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.

Authors:  Bing Cui; Emanuela M Ghia; Liguang Chen; Laura Z Rassenti; Christopher DeBoever; George F Widhopf; Jian Yu; Donna S Neuberg; William G Wierda; Kanti R Rai; Neil E Kay; Jennifer R Brown; Jeffrey A Jones; John G Gribben; Kelly A Frazer; Thomas J Kipps
Journal:  Blood       Date:  2016-11-04       Impact factor: 22.113

4.  Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia.

Authors:  Yun Chen; Liguang Chen; Jian Yu; Emanuela M Ghia; Michael Y Choi; Ling Zhang; Suping Zhang; Elsa Sanchez-Lopez; George F Widhopf; Karen Messer; Laura Z Rassenti; Catriona Jamieson; Thomas J Kipps
Journal:  Blood       Date:  2019-08-13       Impact factor: 22.113

5.  Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.

Authors:  Hanna Karvonen; Robert Perttilä; Wilhelmiina Niininen; Veera Hautanen; Harlan Barker; Astrid Murumägi; Caroline A Heckman; Daniela Ungureanu
Journal:  Oncogene       Date:  2019-01-10       Impact factor: 9.867

Review 6.  Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas.

Authors:  Pavlína Janovská; Vítězslav Bryja
Journal:  Br J Pharmacol       Date:  2017-08-30       Impact factor: 8.739

7.  Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.

Authors:  Jenny Potratz; Amelie Tillmanns; Philipp Berning; Eberhard Korsching; Christiane Schaefer; Birgit Lechtape; Carolin Schleithoff; Rebekka Unland; Karl-Ludwig Schäfer; Carsten Müller-Tidow; Heribert Jürgens; Uta Dirksen
Journal:  Mol Oncol       Date:  2015-12-20       Impact factor: 6.603

8.  IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.

Authors:  Ferran Nadeu; Romina Royo; Guillem Clot; Martí Duran-Ferrer; Alba Navarro; Silvia Martín; Junyan Lu; Thorsten Zenz; Tycho Baumann; Pedro Jares; Xose S Puente; José I Martín-Subero; Julio Delgado; Elías Campo
Journal:  Blood       Date:  2021-05-27       Impact factor: 22.113

9.  Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia.

Authors:  Hana Plešingerová; Pavlína Janovská; Archana Mishra; Lucie Smyčková; Lucie Poppová; Antonín Libra; Karla Plevová; Petra Ovesná; Lenka Radová; Michael Doubek; Šárka Pavlová; Šárka Pospíšilová; Vítězslav Bryja
Journal:  Haematologica       Date:  2017-11-09       Impact factor: 9.941

Review 10.  Aberrant Wnt Signaling in Leukemia.

Authors:  Frank J T Staal; Farbod Famili; Laura Garcia Perez; Karin Pike-Overzet
Journal:  Cancers (Basel)       Date:  2016-08-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.